Lead
This week saw rapid, public disagreement over a U.S.-funded randomized trial of the hepatitis B vaccine in Guinea-Bissau, with the country’s health minister saying the study is suspended pending review and U.S. health officials saying it is still proceeding. The study — partly funded with $1.6 million from the U.S. Centers for Disease Control and Prevention (CDC) — would follow roughly 14,500 newborns and compare a birth dose of hepatitis B vaccine with a schedule that delays that dose until routine visits. Critics, including several prominent physicians and ethicists, have called the design unethical and unnecessary; supporters describe it as a once-in-a-generation chance to measure wider health effects. Conflicting public statements and questions about how the project was selected have driven much of the controversy.
Key Takeaways
- The trial proposal would enroll about 14,500 newborns in Guinea-Bissau and randomize half to receive a birth dose of hepatitis B vaccine and half to receive the vaccine later at standard 6–14-week visits.
- The CDC provided roughly $1.6 million in support for the trial; U.S. Department of Health and Human Services (HHS) has said the protocol is being finalized.
- Guinea-Bissau’s health minister, Quinhin Nantote, said on January 22, 2026, the study is suspended pending review, citing local ethical and coordination concerns; an HHS official later told reporters the study has not been suspended.
- Adult hepatitis B prevalence in Guinea-Bissau is reported near 20%, compared with an estimated ~6% average in parts of sub-Saharan Africa, making early prevention particularly important.
- U.S. pediatric hepatitis B incidence has fallen about 99% since 1991; the CDC reported 10 infant infections from birth exposure in 2020, a figure cited in policy discussions about the birth dose.
- Several leading critics compare the study to past abusive research (notably the Tuskegee syphilis study) and argue that withholding or delaying a recommended vaccine in a high-prevalence setting risks harm and future distrust.
- Outside statisticians have publicly criticized the research group leading the project for overstating results in prior randomized analyses; concerns have also been raised about whether the funding award followed an open, competitive process.
Background
For more than three decades, a hepatitis B vaccine given shortly after birth has been standard policy in many countries, including the United States, and is recommended by the World Health Organization to prevent mother-to-child transmission at delivery. Hepatitis B is a liver infection that can become chronic and later cause cirrhosis or liver cancer; there is no cure, which is why prevention at birth is a cornerstone of public-health programs. In December 2025, CDC advisers voted to reconsider U.S. universal birth-dose policy, a decision shaped in part by a slate of advisers selected by then–Health and Human Services Secretary Robert F. Kennedy Jr., a controversial figure in vaccine policy debates.
Guinea-Bissau does not currently give a universal birth dose, and its government has said it plans to begin routine newborn hepatitis B vaccination in 2028. The Bandim Health Project, a long-standing research group based in Denmark that has worked in Guinea-Bissau for decades, proposed what its website calls a “unique window of opportunity” to study broader health effects of the birth dose before nationwide policy change. That context — a country preparing to roll out birth vaccination in coming years — is central to both the scientific rationale offered by investigators and the ethical concerns voiced by critics.
Main Event
The proposed randomized controlled trial would enroll approximately 14,500 newborns and compare immediate birth vaccination with a delayed schedule where the first hepatitis B dose is given at the same time as other routine vaccines at 6, 10 and 14 weeks. Investigators say the trial’s purpose is not to test efficacy against hepatitis B infection but to evaluate other health outcomes: short-term severe illness, eczema in the first two years, or neurodevelopmental differences up to age five.
On January 22, 2026, Guinea-Bissau’s Minister of Public Health, Quinhin Nantote, told reporters the study is suspended or may be canceled, saying a local ethics committee that had approved the protocol lacked the required technical resources and had not coordinated with other national authorities. He cited recent political upheaval — a November military coup that reshaped senior government posts — and described misinformation and weak social communication as factors complicating national decision-making.
Africa CDC said it was dispatching a team to assist Guinea-Bissau’s evaluation and emphasized that local officials retain final authority. Shortly after the minister’s remarks, an unnamed official at the U.S. Department of Health and Human Services emailed NPR to say the study had not been suspended and that the protocol was being finalized, underscoring the mixed public messaging around the project. Investigators from the Bandim Health Project have defended the study online, arguing trial teams will increase timely vaccination coverage compared with routine services and that no newborn will receive fewer vaccines because of the research.
Analysis & Implications
Ethically, the central objection is straightforward: critics contend the trial withholds a WHO-recommended intervention from some newborns in a setting with very high hepatitis B prevalence, potentially exposing infants to preventable infection during a critical window. Opponents invoke historical abuses — most notably the Tuskegee syphilis study — to underscore the gravity of conducting randomized research that appears to delay a protective intervention among a vulnerable population.
Proponents frame the study as answering a different question: whether the birth dose has unintended effects on broader child health outcomes. They argue that because Guinea-Bissau has not yet implemented universal birth-dose vaccination, the randomized design would simply compare two feasible policy timings and could yield data relevant to other low- and middle-income settings. That scientific argument depends on whether the question is sufficiently valuable and whether trial conduct meets strict ethical safeguards in consent, monitoring and post-trial access.
The political dimension amplifies the scientific debate. Questions about the CDC’s $1.6 million award process and the involvement of advisors aligned with vaccine-skeptical positions raise concerns about politicization of research funding. If the award bypassed competitive peer review, critics say, it undermines confidence in both the study and the institution that sponsored it, especially when the chosen investigators have drawn methodological criticism in the past.
Comparison & Data
| Metric | Guinea-Bissau | Sub-Saharan avg. | United States |
|---|---|---|---|
| Adult hepatitis B prevalence | ~20% | ~6% | <1% |
| Planned trial enrollment | 14,500 newborns | — | — |
| CDC support cited | $1.6 million | — | — |
| U.S. pediatric HBV decline since 1991 | — | — | ~99% reduction |
| Infant infections from birth exposure (2020) | — | — | 10 cases |
The table highlights why the stakes differ across settings: a near-20% adult prevalence in Guinea-Bissau means that delaying a birth dose could carry much higher absolute risk of perinatal transmission than in lower-prevalence countries. Conversely, the U.S. experience — a 99% decline in pediatric hepatitis B since routine neonatal vaccination began — is offered by proponents as evidence of the vaccine’s long-term population benefit, even as some U.S. advisers voted in December 2025 to reconsider universal birth-dose guidance.
Reactions & Quotes
Several leading vaccine experts immediately criticized the design as unethical and potentially harmful, framing the trial as an unnecessary experiment in a high-prevalence setting. Their concerns focus on risk to infants, historical memory of exploitative research, and the possibility of long-term erosion of trust in health services.
“[The Guinea-Bissau study] is highly unethical and cruel and frankly dishonest.”
Dr. Paul Offit, Vaccine Education Center, Children’s Hospital of Philadelphia
Offit’s remark reflects long-standing professional alarm about trials that appear to delay an effective preventive intervention; his comments also highlight the moral intensity of invoking historical abuses. Supporters of the research reject that characterization, saying the project studies different outcomes and could strengthen routine vaccination delivery by increasing outreach and coverage.
Africa CDC emphasized national sovereignty while offering technical support, signaling regional concern about process and oversight but also deference to local decision-making authority.
“It’s not a foreign country that will come and say this one will take place. It’s the sovereignty of the country.”
Dr. Jean Kaseya, Director-General, Africa CDC
Kaseya’s statement frames the dispute as one of national governance and capacity: Africa CDC said it would send a team to help evaluate the protocol, while underlining that Guinea-Bissau’s authorities have final say. That response aims to balance respect for national decision-making with a regional role in safeguarding research ethics.
Unconfirmed
- Whether enrollment actually began before the January 22, 2026 suspension announcement: public reports conflict and there is no independent verification of trial start dates.
- Whether the local ethics committee lacked the technical resources claimed by the health minister: the minister asserted this, but documentation of the committee’s capacity and approvals has not been publicly released.
- Allegations that the Bandim Health Project was hand-picked without a competitive award process: critics have raised this concern, but a full procurement record has not been made public.
Bottom Line
The dispute over the Guinea-Bissau hepatitis B trial centers on a clash between scientific curiosity and ethical obligation in a high-prevalence, politically sensitive setting. If the trial proceeds, it must meet stringent ethical standards, transparent oversight and clear community engagement to avoid harming infants and eroding public trust. If it is halted, the debate will continue about how to study potential broader effects of vaccines without exposing vulnerable populations to avoidable risk.
Observers should watch three developments closely: the outcome of Guinea-Bissau’s national review and any Africa CDC advisory, the CDC/HHS explanation of the award and protocol status, and whether independent ethics and statistical reviewers publish assessments of the proposed design. Those items will largely determine whether the project can be salvaged with stronger safeguards or must be abandoned.
Sources
- NPR (news report on trial, Jan 22, 2026) — independent journalism
- Africa CDC (regional public health agency) — official statement referenced
- Bandim Health Project (research group) — investigators’ information and trial description
- U.S. Department of Health and Human Services (HHS) — official statements regarding U.S. stance and funding
- Vaccine journal (peer-reviewed) — independent methodological critique referenced in coverage